Small Molecule Cyclotriazadisulfonamide Abrogates the Upregulation of the Human Receptors CD4 and 4-1BB and Suppresses In Vitro Activation and Proliferation of T Lymphocytes
The small molecule cyclotriazadisulfonamide (CADA) down-modulates the human CD4 receptor, an important factor in T cell activation. Here, we addressed the immunosuppressive potential of CADA using different activation models. CADA inhibited lymphocyte proliferation with low cellular toxicity in a mi...
Main Authors: | Elisa Claeys, Eva Pauwels, Stephanie Humblet-Baron, Becky Provinciael, Dominique Schols, Mark Waer, Ben Sprangers, Kurt Vermeire |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.650731/full |
Similar Items
-
Accelerating Cancer Immunotherapy Through 4-1BB Activation
by: Todd eBartkowiak, et al.
Published: (2015-06-01) -
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
by: Juan M. Zapata, et al.
Published: (2018-11-01) -
Hu.4-1BB-Fc fusion protein inhibits allergic inflammation and airway hyperresponsiveness in a murine model of asthma
by: Byoung-Ju Kim, et al.
Published: (2011-09-01) -
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
by: Dinh-Toi Chu, et al.
Published: (2019-04-01) -
CD137<sup>+</sup> T-Cells: Protagonists of the Immunotherapy Revolution
by: Alessio Ugolini, et al.
Published: (2021-01-01)